利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.078 秒)

    Macromolecule-containing sustained release intraocular implants and related methods
    1.
    发明申请
    Macromolecule-containing sustained release intraocular implants and related methods 审中-公开
    含大分子的持续释放眼内植入物及相关方法

    公开(公告)号：US20050281861A1

    公开(公告)日：2005-12-22

    申请号：US11116698

    申请日：2005-04-27

    申请人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Tom Malone ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61F2/00 ,  A61F9/00 ,  A61K9/00 ,  A61K9/16 ,  A61K31/724 ,  A61K39/395 ,  A61K47/34 ,  A61K47/40 ,  A61K47/48 ,  A61K48/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40

    摘要： Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis agents, ocular hemorrhage treatment agents, non-steroidal anti-inflammatory agents, growth factor inhibitors (such as VEGF inhibitors), growth factors, cytokines, antibodies, oligonucleotide aptamers, siRNA molecules and antibiotics. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括非神经毒性大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 大分子治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可保留其三维结构，或者治疗剂可具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成剂，眼出血治疗剂，非甾体抗炎剂，生长因子抑制剂（例如VEGF抑制剂），生长因子，细胞因子，抗体，寡核苷酸适体，siRNA 分子和抗生素。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Anti-angiogenic sustained release intraocular implants and related methods
    2.
    发明申请
    Anti-angiogenic sustained release intraocular implants and related methods 审中-公开
    抗血管生成持续释放眼内植入物及相关方法

    公开(公告)号：US20070059336A1

    公开(公告)日：2007-03-15

    申请号：US11364687

    申请日：2006-02-27

    申请人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    发明人： Patrick Hughes ,  Thomas Malone ,  Gerald De Vries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Peter Baciu ,  Scott Whitcup

    IPC分类号： A61K38/18 ,  A61K39/395

    CPC分类号： A61K48/0041 ,  A61K9/0051

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂可以选自抗血管生成肽，激素和核酸试剂。 植入物可以置于眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Sustained release intraocular drug delivery systems
    4.
    发明申请
    Sustained release intraocular drug delivery systems 审中-公开
    持续释放眼内药物递送系统

    公开(公告)号：US20060182783A1

    公开(公告)日：2006-08-17

    申请号：US11370301

    申请日：2006-03-08

    申请人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    发明人： Patrick Hughes ,  Gerald Devries ,  Jeffrey Edelman ,  Wendy Blanda ,  Lon Spada ,  Robert Lyons

    IPC分类号： A61K48/00 ,  A61F2/00

    CPC分类号： A61K9/0051 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/1647 ,  A61K31/724 ,  A61K47/34 ,  A61K47/40 ,  A61K48/0041

    摘要： Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

    摘要翻译： 生物相容性眼内药物递送系统包括抗血管生成大分子治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三维结构，但保持其治疗活性。 治疗剂含有选自抗血管生成肽和核酸试剂的组分。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。

    Memantine intravitreal implants
    5.
    发明申请
    Memantine intravitreal implants 审中-公开
    美金刚玻璃体内植入物

    公开(公告)号：US20050244473A1

    公开(公告)日：2005-11-03

    申请号：US11117879

    申请日：2005-04-29

    申请人： Patrick Hughes ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang

    发明人： Patrick Hughes ,  Lon Spada ,  Hiroshi Sugimoto ,  Wendy Blanda ,  James Chang

    IPC分类号： A61K9/00 ,  A61K31/13 ,  A61F2/00

    CPC分类号： A61K9/0051

    摘要： Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.

    摘要翻译： 生物相容性眼内植入物包括抗兴奋性毒性剂和可生物降解的聚合物，其有效促进抗兴奋性毒性剂长时间释放到眼睛中。 植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。

    Compositions and methods for localized therapy of the eye
    7.
    发明申请
    Compositions and methods for localized therapy of the eye 审中-公开
    眼睛局部治疗的组成和方法

    公开(公告)号：US20050181017A1

    公开(公告)日：2005-08-18

    申请号：US11039192

    申请日：2005-01-19

    申请人： Patrick Hughes ,  Orest Olejnik ,  Scott Whitcup ,  James Burke

    发明人： Patrick Hughes ,  Orest Olejnik ,  Scott Whitcup ,  James Burke

    IPC分类号： A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K31/00 ,  A61K47/36

    CPC分类号： A61K38/13 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/10 ,  A61K9/14 ,  A61K31/00 ,  A61K47/36 ,  Y10S514/912

    摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

    摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括促进在眼睛的视网膜色素上皮中形成治疗剂的浓缩区域的难溶性治疗剂的小颗粒。 通过将治疗剂与眼科可接受的聚合物组分组合来形成颗粒。 颗粒具有小于约3000纳米的尺寸，并且在一些情况下小于约200纳米。 组合物的一个实例包括曲安奈德的颗粒和透明质酸的尺寸小于约3000纳米。

    Method of sterilization of polymeric microparticles
    10.
    发明申请
    Method of sterilization of polymeric microparticles 审中-公开
    聚合物微粒灭菌方法

    公开(公告)号：US20050003007A1

    公开(公告)日：2005-01-06

    申请号：US10614408

    申请日：2003-07-02

    申请人： Michele Boix ,  Christian Sarrazin ,  Patrick Hughes ,  Marina Do ,  Isabelle Maroteaux

    发明人： Michele Boix ,  Christian Sarrazin ,  Patrick Hughes ,  Marina Do ,  Isabelle Maroteaux

    IPC分类号： A61K9/16 ,  A61K31/455 ,  A61K41/00 ,  A61L2/08 ,  A61L2/10 ,  A61L2/12 ,  A61K9/14

    CPC分类号： A61L2/087 ,  A61K9/1647 ,  A61K31/455 ,  A61K41/0019 ,  A61L2/081 ,  A61L2/10 ,  A61L2/12

    摘要： This invention relates to the sterilization of polymeric material by irradiation for use in a body of a mammal. We have surprisingly discovered that the sterilization of polymeric materials for use in a mammal by irradiation is improved by reducing the temperature at which the irradiation is carried out. One aspect of this invention relates to a sterilized polymeric material for use in a body of a mammal wherein said polymeric material is sterilized by irradiation at a reduced temperature Another aspect of this invention relates to methods of sustained delivery of a therapeutically active agent to a mammal by using a polymeric material that has been sterilized at a reduced temperature by irradiation.

    摘要翻译： 本发明涉及通过照射用于哺乳动物体内的聚合材料的灭菌。 我们惊奇地发现，通过降低进行照射的温度来改善通过照射对哺乳动物使用的聚合材料的灭菌。 本发明的一个方面涉及用于哺乳动物身体的灭菌聚合物材料，其中所述聚合物材料通过在降低的温度下照射而灭菌。本发明的另一方面涉及将治疗活性剂持续递送至哺乳动物的方法 通过使用通过照射在降低的温度下灭菌的聚合物材料。